Biocytogen

?? The Power of Mice in Research ?? Mice share over 95% of their genes with humans, making them essential in advancing biomedical research and drug discovery. They’re used in various fields, from cancer research to gene-editing breakthroughs, and continue to play a crucial role in developing new therapies. Vote below and let us know what you think! ?? #Biotech #MiceInResearch #CancerResearch #Immunotherapy #GeneEditing #DrugDiscovery #MedicalInnovation

?? Happy St. Patrick’s Day from Biocytogen! ?? We’re feeling extra lucky to be part of such an incredible biotech community! Just like the perfect four-leaf clover, groundbreaking drug discovery takes the right mix of science, strategy, collaboration—and maybe just a little bit of biotech magic. ??? A huge shoutout to Lincoln Property Company for hosting us—we had a fantastic time connecting, collaborating, and celebrating innovation! At Biocytogen, we’re on a mission to turn cutting-edge science into life-changing treatments, using our therapeutic antibody assets and preclinical solutions to speed up drug discovery. Because even in science, a little luck can go a long way—while cutting-edge innovation makes the real magic happen! ?? Wishing everyone a day filled with luck, laughter, and biotech breakthroughs! ???? #HappyStPatricksDay #Biocytogen #LuckMeetsScience #BiotechBreakthroughs #ThankYouLincolnProperty

?? Advancing Immuno-Oncology Therapies with Biocytogen’s Target Humanized Mice ?? Immuno-oncology (IO) is transforming cancer treatment by harnessing the immune system to fight tumors. From immune checkpoint inhibitors that “release the brakes” on T cells, to ADCs delivering drugs directly to cancer cells, T cell engagers (TCEs) guiding immune cells to tumors, and CAR-T therapies reprogramming T cells to attack cancer, IO is advancing safer, more precise treatments. Biocytogen’s drug-targeted humanized mice accelerate IO drug discovery by enabling in vivo evaluations of drug efficacy, toxicity, and PK/PD in a human-relevant context. These models incorporate single or multiple human targets, such as immune checkpoints, tumor microenvironment molecules, and combinations like CD3E/CD3EDG on T cells with tumor-associated antigens (TAAs) for TCE evaluations. We also assess CAR-T cell efficacy across various tumor models, including in immunodeficient B-NDG mice, driving the discovery of innovative therapies.???? Discover how our models can fast-track your therapies—connect with us today! #Biocytogen #DrugDiscovery #OncologyInnovation #ImmunoOncology #CancerTreatment #ImmuneCheckpoint #ADC #TCellEngager #CART #HumanizedMice

Tackling TNBC with Biocytogen’s Antibody Portfolio?? Triple-negative breast cancer (TNBC) is one of the most challenging subtypes of breast cancer, accounting for 15–20% of all cases. Because TNBC lacks ER, PR, and HER2 expression, it does not respond to traditional endocrine or HER2-targeted therapies. While chemotherapy remains a primary treatment option, its limited efficacy often leads to drug resistance and a poor prognosis. At Biocytogen, we leverage our RenMice? antibody discovery platform to develop highly specific, high-affinity antibodies with strong therapeutic potential for TNBC, such as our PCC-stage asset, PTK7 × TROP2 bispecific ADC (BCG033), which has demonstrated superior anti-tumor efficacy in vivo compared to benchmark ADCs.???? Contact us today to learn more about our TNBC assets! #TNBC #BreastCancerResearch #Immunotherapy #AntibodyDiscovery #Oncology #CancerTherapeutics #Biocytogen #RenMice #bsADC #ADC

?? Unlocking the Power of HLA in Immunotherapy, Vaccine Development, and Transplant Studies?? Human Leukocyte Antigens (HLAs) are vital components of the immune system, distinguishing between "self" and "non-self." They interact with T-cell receptors to present foreign antigens, triggering targeted immune responses. HLAs play critical roles in biomedical research: ? Cancer immunotherapy – Tumors can evade immune detection by downregulating HLA, making it a key research focus. ? Organ transplantation – Precise HLA typing improves compatibility and reduces rejection risk. ? Autoimmune diseases – Certain HLA alleles are linked to autoimmune conditions, aiding in early diagnosis and personalized treatment. ? Vaccine development – Individual variations in HLA can influence vaccine efficacy, highlighting their importance in developing more effective vaccines. At Biocytogen, we’ve developed HLA-humanized mouse models on C57BL/6 and immunodeficient B-NDG backgrounds, where human HLA genes replace their murine counterparts. These models serve as powerful preclinical tools for immuno-oncology, vaccine development, and transplantation research, enhancing reliability and translational potential. Explore how our models can accelerate your immunotherapy breakthroughs! ???? #HLA #Immunotherapy #CancerResearch #PreclinicalModels #TranslationalScience #AutoimmuneResearch #VaccineDevelopment #Biocytogen #TransplantStudy #HumanizedMice

?? Keynote Speaker Spotlight: SAPA-NE 2025 Antibody Workshop ?? We're thrilled to spotlight Dr. Qiurong Wang, Business Development Director at Biocytogen! ?? Speech Topic: "Accelerating Bi- & Multi-Specific and ADC Drug Discovery with Drug-Targeted Humanized Mouse Models" Dr. Wang will share her expertise in leveraging advanced humanized mouse models to fast-track the development of innovative bi-specific, multi-specific, and Antibody Drug Conjugate (ADC) therapies. ?? When: Saturday, March 29, 2025 | 1:00 PM – 5:00 PM EDT ?? Where: Lilly Seaport Innovation Center, Boston, MA ?? Reserve your spot now: https://lnkd.in/eTpUXDck Special thanks to our event sponsors: GenScript and Kactus Join us to gain insights, connect with leaders, and shape the future of therapeutic innovation! ?? #SAPA_NE #SAPANE #BiotechInnovation #ADC #HumanizedModels #DrugDiscovery #KeynoteSpeaker #Networking #GenScript #Kactus

?? Celebrating the Women of Biocytogen & Women in Biotech! ?? This Women History Month, we honor the brilliant women driving innovation at Biocytogen and across the biotech industry. Women make up nearly 50% of the life sciences workforce, yet remain underrepresented in leadership roles. At Biocytogen, we celebrate the talent, dedication, and breakthroughs led by our incredible female colleagues—pushing the boundaries of science and shaping the future of biotech. As a token of appreciation, we’re sharing roses and cakes to recognize the contributions of the women who make our workplace thrive. Your passion, expertise, and impact do not go unnoticed! Here’s to empowering women in STEM, breaking barriers, and creating a more inclusive future. ???? #WomensPrideMonth #WomenInBiotech #WomenInSTEM #Biocytogen

Women’s History Month – Let’s Celebrate Women in Biotech! ???? From groundbreaking discoveries to leading biotech companies, women are driving innovation like never before! ?? But there’s still work to be done to ensure greater representation and support in the industry. Vote and share your thoughts in the comments! Let’s keep the momentum going for women in STEM! ? #WomensHistoryMonth #WomenInBiotech #BreakingBarriers

?? Spring into a New Career! ?? As the days get longer and the flowers start to bloom, it’s the perfect time for new beginnings—especially in your career! Whether you're looking to grow, innovate, or take on fresh challenges, Biocytogen is hiring, and we want you to be part of our journey! ? Join our dynamic Boston team and contribute to groundbreaking discoveries that shape the future of healthcare. Let’s make this season one of growth, opportunity, and new adventures—together! ???? ?? Ready to take the next step? Reach out to [email protected] to explore open positions. ?? Explore Biocytogen Careers: https://lnkd.in/eDb66tP ?Scientist for Content Marketing: https://lnkd.in/evg5jCiH ?Scientist/Sr. Scientist for in vivo Pharmacology: https://lnkd.in/etyKjf79 ?Husbandry Technician: https://lnkd.in/emUi5faM ? Scientist/Sr. Scientist-Preclinical Antibody Drug Development: https://lnkd.in/eTTnvQXb ?Business Development Manager-Product & Services (GC): https://lnkd.in/efNddXiV #SpringIntoSuccess #Biocytogen #Hiring #BiotechCareers #NewSeasonNewOpportunities #JobSearch

?? In Vivo CAR-T & HCAbs: A Powerful Duo Advancing Cancer Therapy ?? Traditional CAR-T therapy relies on ex vivo T-cell engineering, facing challenges like long manufacturing, high costs, and patient variability. But what if we could generate CAR-T cells directly in the body? In vivo CAR-T overcomes these hurdles by generating CAR-T cells within the body through targeted delivery, reducing wait times, enhancing safety, and eliminating the need for lymphodepleting chemotherapy. Leveraging Biocytogen’s proprietary RenNano? platform for fully human heavy-chain-only antibody (HCAb) discovery, we’ve developed high-specificity, high-affinity delivery systems to address key challenges in in vivo CAR-T development: ? Precision Targeting – HCAb-based modules selectively bind to T-cell surface markers, enabling efficient in vivo T-cell capture and genetic reprogramming. ? Efficient Delivery – Nanoscale carriers seamlessly penetrate tissues and transport therapeutic payloads across biological barriers. ? Enhanced Safety – Fully human antibodies minimize immunogenicity and anti-drug antibody (ADA) risks. Contact us to learn more!???? #CART #InVivoCART #CellTherapy #HCAb #Immunotherapy #Biocytogen #RenNano #Oncology #GeneTherapy #DrugDiscovery?